contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


redeye-scibase-q42024-investing-in-us-growth

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

SciBase Holding is a global medical technology group specialized in diagnostics and prevention in dermatology. The company develops, produces and commercializes Nevisense, a patient-centered platform that combines AI (artificial intelligence) with EIS technology to enable early detection and intervention of skin cancer and other skin diseases. Nevisense is based on over 20 years of research at Karolinska Institutet, the headquarters are in Stockholm.

The stock is surging for some reason. I don’t see any news, at least.

Now, apparently, a solution is being sought in connection with a share issue for this difficult capital structure due to TO2 warrants. Warrants are being converted into shares here, so that two warrants are exchanged for one share                    Inderes              The Board of Directors in SciBase resolves on an offer to repurchase...    The Board of Directors in SciBase Holding AB (publ) ("SciBase" or the "Company") has today resolved to make a repurchase offer for all 498,534,835 outstanding warrants of series TO 2 in the ...                             That TO2 warrant structure made the company’s valuation exceptionally complex during our company coverage, so, fundamentally, evaluating the company as an investment will become easier with this

Where can I buy those warrants? They sound like a very interesting investment if the maturity period is that long.

Thanks for the insights. Can more experienced investors estimate how common it is for the option exercise period to be set so far out, all the way to spring 2029? It feels like a very long timeframe. This is indeed a big hindrance to the share price increase, especially since such a huge number of options are redeemable. Or how do the rest of you see it?

Interesting company, and with the increasing prevalence of melanoma, the market should grow. I personally held a small position in this, but those warrants seem to prevent a larger price increase. In addition, revenue growth has been so slow that a new share issue (and more warrants) might be on the horizon again by the end of the year. The number of employees has now slightly increased, apparently the US sales organization has been strengthened?

Unfortunately, the coverage ended a while ago, so we don’t have fresh comments available. If one considers the share price formation, this point about the termination of coverage is very essential to keep in mind:  We highlight that the high number of TO2 warrants (strike price SEK 0.42) has a significant impact on the valuation of the company and investors should evaluate the warrants’ claim on the company’s equity value when assessing the valuation of the stock.

Coverage agreement terminated and coverage ended in December 2024:                  Inderes              SciBase: We are discontinuing coverage - Inderes    We are discontinuing our coverage of SciBase as the company has terminated the research service agreement. Consequently, we will no longer give the stock a target price (prev. 0.45 SEK) or recommendation (prev. Reduce).

Scibase Holding

Redeye saw a Q4 report in which sales exceeded our estimates. Growth was strong across all markets. The highlight is the growth in the US, which was supported by the cost increases. We have ...

<div class="mfn-body"><p>Redeye saw a Q4 report in which sales exceeded our estimates. Growth was strong across all markets. The highlight is the growth in the US, which was supported by the cost increases. We have trimmed our estimates downward for 2025-2027e, primarily due to increased sales costs in the US. With these changes and rolling over to a new year, we lower our fair value range to SEK 0.37-3.5 and our Base case to SEK 1.4(1.6) per share. Following this report, we are changing the lead analyst.</p><p><a rel="noopener" href="https://www.redeye.se/research/1083841/scibase-q42024-investing-in-us-growth?utm_source=MFN&amp;utm_medium=pmcour">Read more and download the Research Update.</a><br>&nbsp;<br>Follow companies at Redeye to receive the latest equity research within Life Science and Technology.<br>&nbsp;<br>This is a press release from Redeye - Research Powered Investment Banking. <a rel="noopener" href="https://www.redeye.se/">www.redeye.se/</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/4d7c2463-09f0-4f45-8780-9df08526b0ab/scibase-q42024-investing-in-us-growth.pdf" class="mfn-generated mfn-primary">SciBase Q4’2024 - Investing in US growth</a></p></div>